Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Open accessThe DOI matches its Crossref record; 41 of the 51 references it cites were found in a registry or an index.
Abstract
Significance: Glucagon-like peptide-1 receptor agonists have become established as a leading class of diabetes medications. However, these peptide-based drugs are administered by subcutaneous injection or, in one case, by a complex oral dosing regimen. We now report the discovery of LY3502970, a potent and selective small-molecule GLP-1R agonist. LY3502970 exhibits preclinical pharmacology equivalent to a marketed injectable GLP-1R agonist and possesses pharmacokinetic properties compatible with oral dosing in humans. Cryoelectron microscopy (cryo-EM) studies reveal an ECD-driven receptor binding mode for LY3502970 that provides a favorable pharmacological profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. Trp33ECD mediates key interaction with LY3502970 and the surrounding region. (A) Amino acid sequence comparison of the ECD regions for GLP-1Rs of different species. (B) LY3502970 increases cAMP accumulation in HEK293 cells expressing a chimeric form of the mouse GLP-1R (domains shown in green) where the N-terminal 142 residues have been replaced by the corresponding region of the human GLP-1R (domains shown in blue). (C) Mutation of Ser33ECD to Trp33ECD in the mouse GLP-1R enables LY3502970 to stimulate receptor-induced cAMP accumulation, while the reciprocal mutation (D) in the human GLP-1R abolishes compound function. The chimera and mutant data are presented as the mean ± SD of three independent experiments. (E) Trp33ECD interacts with LY3502970 and residues on TM2, ECL1, and ECL2. Residues and ligands are shown by sticks except Trp33ECD, which is also shown by spheres. Hydrogen bonds are indicated by dashed lines. (F) GLP-1R ECD orientation in the LY3502970 bound structure stabilized by aromatic interactions with ECL1. (G) The unique ECD orientation of ECD in the LY3502970 bound structure as a result of the unique Trp33ECD position. The structures of GLP-1R bound to LY3502970 (7TM in green, ECD in blue green, LY3502970 in magenta), GLP-1 (yellow, PDB ID code 6VCB), and peptide 5 (gray, PDB ID code 5NX2) are aligned. Trp33ECD is shown by a stick. Other peptide bound GLP-1R structures (GLP-1, PDB ID code 5VAI; ExP5, PDB ID code 6B3J) are not shown here, but their ECD orientations are very similar to GLP-1 bound structure 6VCB in yellow. (H and I) Competitive inhibition of [125I]GLP-1(7-36) binding to membranes isolated from cells expressing the human GLP-1R (H) or human W33S GLP-1R (I). Data are represented as the mean ± SD of three independent experiments.](https://figures.cochat.ai/paper-figures/acc41917547f432fb9ba49113ec198cd/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-2.jpg)


![Fig. 5. LY3502970 enhances glucose-stimulated insulin secretion and reduces food consumption in cynomolgus monkeys. (B–E) Effects of LY3502970 in IVGTT experiments. (A) Schematic diagram of the IVGTT procedure in anesthetized cynomolgus monkeys. Dosing of LY3502970 or exenatide was performed by manual bolus injection, followed by continuous infusion for 80 min. Forty minutes after initiating dosing of vehicle or the drug, glucose was administered intravenously. (B and C) Effect of LY3502970 (B) or exenatide (C) on blood glucose levels. (D and E) Effect of LY3502970 (D) or exenatide (E) on serum insulin levels. Data are represented as the mean ± SEM (n = 7). Significantly different from vehicle 1 or vehicle 2 by Dunnett’s test at *P < 0.025 and **P < 0.005 (one tailed), respectively. Vehicle 1: PEG400/PG/Gly NaOH buffer (pH 9), vehicle 2: 0.05% Tween80 PBS. (F and G) Mean food consumption following administration of LY3502970 (F) or exenatide (G). Cynomolgus monkeys were administered LY3502970, exenatide, or vehicle once daily for 5 d with a 2 d recovery period using an 8 × 5 cross-over design. Food consumption during the 90 min period after feeding was measured. Data are represented as the mean ± SEM (n = 8). Significantly different from the vehicle group by Dunnett’s test at **P < 0.005 (one tailed). Vehicle: dimethyl sulfoxide (DMSO)/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + 0.05% Tween80 PBS [s.c.], LY3502970: LY3502970 [p.o.] + 0.05% Tween 80 PBS [s.c.], exenatide: DMSO/Cremophor/PEG400/Gly-NaOH buffer (pH 10) [p.o.] + exenatide [s.c.].](https://figures.cochat.ai/paper-figures/a9b9ab625235418ca4ecc2d8317f67c4/structural-basis-for-glp-1-receptor-activation-by-ly3502970-an-orally-active-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More specifically, orforglipron is a potent partial GLP-1 RA which is biased towards G-protein activation over to β-arrestin recruitment at the GLP-1 receptor [23].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, orforglipron demonstrated a terminal half-life of 29-49 h in a phase 1b study in people with T2D, which allows once-daily oral dosing [25,28].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous report, treatment with orforglipron was found to promote glucose-dependent insulin secretion after a glucose challenge [25].”
From Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orforglipron is an orally administered, non-peptide GLP-1 receptor agonist that can be taken once daily. However, it binds differently to the GLP-1 receptor compared to native GLP-1, thereby inducing G-protein activation rather than beta-arrestin recruitment [107].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [107]
Experimental — accuracy not yet measuredIn the citing paper
“As a small molecule, orforglipron is chemically stable in the acidic gastric environment and is not a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33,34,35”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 1×
“This starting model was then subjected to iterative rounds of manual and Real Space Refinement in Coot (47, 48) and Phenix (49), respectively.”
MethodGuide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy
Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. (2017) · Nature Methods · doi:10.1038/nmeth.4193 · Cited by 7,777 · cited 2×
“S. Q. Zheng et al., MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy.”
MethodPHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621 · cited 1×
“Bayesian polishing and CTF refinement (46) were applied to further improve the map, resulting in a 3.”
MethodMolProbity: More and better reference data for improved all‐atom structure validation
Williams, C. J., Headd, J. J., Moriarty, N. W., Prisant, M. G., Videau, L. L., Deis, L. N., Verma, V., Keedy, D. A., Hintze, B. J., Chen, V. B., et al. (2018) · Protein Science · doi:10.1002/pro.3330 · Cited by 4,599 · cited 1×
“The final model was visually inspected for general fit to the map, and geometry was further evaluated using Molprobity (50).”
MethodGctf: Real-time CTF determination and correction
Zhang, K. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.11.003 · Cited by 3,537
Guide for the Care and Use of Laboratory Animals: Eighth Edition -- Tamil Version
Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Studies, D. O. E. A. L., & National Research Council (2011) · National Academies Press eBooks · doi:10.17226/25801 · Cited by 1,118
Research works printed but not linked: 1
- Nguyen T., Drug structures displayed for the first time in Orlando. Chem. Eng. News (2019).
Cited by
Items 101–200 of 231
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 13
What Happens in Successful Optimizations? A Survey of 2018–2024 Literature
Leeson, P. D. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03171 · Cited by 13
GLP-1R mediates idebenone-reduced blood glucose in mice
Zhao, X., Zeng, Q., Yu, S., Zhu, X., Hu, B., Deng, L., Zhang, Y., & Liu, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117202 · Cited by 10
Sonne, N., Roque, M., Zachariassen, L. F., Porsgaard, T., Pors, S. E., Cavalera, M., Jones, C., Osborn, O., Thorbek, D. D., Riis, M. L., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106121 · Cited by 9
“13,14,28,49 In our study, orforglipron and danuglipron displayed potencies comparable to GLP-1 (7–37) and semaglutide with respect to cAMP production in isolated β -cells from hGLP1R mice.”
InfluentialA Brain Reward Circuit Inhibited By Next-Generation Weight Loss DrugsPreprint
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A. K., Li, O. D.-A., Ogilvie, S., Keeler, A. B., Tian, G., Koita, O., Shi, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628169 · Cited by 8
Another milestone in the evolution of GLP-1-based diabetes therapies
Nauck, M. A., Quast, D. R., & Meier, J. J. (2021) · Nature Medicine · doi:10.1038/s41591-021-01394-7 · Cited by 7
Li, B., Yang, M. Y., Kim, S., & Goddard, W. A. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c08128 · Cited by 9
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations
Kim, D.-H., & Kim, J.-E. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00762-6 · Cited by 10
““AI and digital twin-based drug formulation optimization”) (Kawai et al. 2020 ; Griffith et al. 2022; Frias et al. 2023; Saxena et al. 2023; Wharton et al. 2023).”
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
Morse, B. L., Bhattachar, S., Ma, X., Coutant, D. E., Czeskis, B., Nicoll, C., & Cassidy, K. C. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1594 · Cited by 7
Small-Molecule GLP-1 Receptor Agonists: A Promising Pharmacological Approach
Șeremet, O. C., Pușcașu, C., Andrei, C., Nițulescu, G., Zbârcea, C. E., & Olaru, O. T. (2025) · Medicina · doi:10.3390/medicina61111902 · Cited by 12
“This biased agonism profile is linked to sustained receptor responsiveness and may attenuate certain (AEs) typically associated with full GLP-1R agonists [75,76].”
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Deganutti, G., Pipito, L., Rujan, R. M., Weizmann, T., Griffin, P., Ciancetta, A., Moro, S., & Reynolds, C. A. (2025) · eLife · doi:10.7554/elife.96513 · Cited by 7
Physiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Chow, E. W.-K., & Chow, E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02381-5 · Cited by 7
A brain reward circuit inhibited by next-generation weight-loss drugs in mice
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A., Li, O., Ogilvie, S., Keeler, A. B., Tian, G., Shi, Y., Koita, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10444-4 · Cited by 23
Alturki, M. S., Alkhodier, R. A., Gomaa, M. S., Hussein, D. A., Tawfeeq, N., Khzem, A. H. A., Pottoo, F. H., Albugami, S. A., Aldawsari, M. F., & Rants’o, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136131 · Cited by 7
“Compounds such as orforglipron, danuglipron, and TT-OAD2 have shown promising pharmacokinetic profiles, and early clinical results suggest that they could be an efficient and practical alternative to existing peptide oral GLP-1RAs (Figure 2) [17–23].”
Wu, Y., von Hauff, I., Jensen, N., Rossner, M. J., & Wehr, M. C. (2022) · Biosensors · doi:10.3390/bios13010048 · Cited by 6
Chalse, M. N., Aswar, U. M., & Pethkar, A. V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104941 · Cited by 6
Kang, S., Kim, N. H., & Yu, Y. G. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.10.071 · Cited by 6
Deganutti, G., Pipitò, L., Rujan, R., Weizmann, T., Griffin, P., Ciancetta, A., Moro, S., & Reynolds, C. A. (2024) · eLife · doi:10.7554/elife.96513.1 · Cited by 6
Ohwaki, K., Nakamura, C., Nasu, R., Takenouchi, K., & Hirase, T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70157 · Cited by 5
“Orforglipron is a partial agonist of the glucagon-like peptide-1 receptor, which primarily activates G-protein coupled signaling pathways over beta-arrestin recruitment 3 .”
Yuliantie, E., Trinh, P. N. H., Hick, C. A., Ebenhoch, R., Nar, H., Weichert, D., Christopoulos, A., Sexton, P. M., & Wootten, D. L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116483 · Cited by 5
GPCR Biased Signaling in Metabolism
Zhang, Z., & Li, Z. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2025_774 · Cited by 6
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 9
“The biased agonism of exenatide, favoring G protein signaling over β -arrestin recruitment, contributes to its beneficial effects on glucose metabolism while potentially reducing receptor desensitization and side effects such as nausea [47].”
InfluentialIslam, M. S., Monir, S. B., Haque, N., Vabna, M. A., Fan, J., Li, Y., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710157 · Cited by 12
“Unlike conventional full agonists, LY3502970 preferentially activates G-protein signaling while minimizing b -arrestin recruitment, a property expected to enhance metabolic ef fi cacy while reducing adverse gastrointestinal effects (146).”
Wang, H., Hu, W., Xu, T., Yuan, Y., Liu, D., & Wüthrich, K. (2023) · iScience · doi:10.1016/j.isci.2023.106918 · Cited by 4
Bridge, L., Chen, S., & Jones, B. J. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111153 · Cited by 7
Supramolecular oral delivery technologies for polypeptide-based drugs
Chen, J., Liu, T., Wang, M., Lü, B., Bai, D., Shang, J., Chen, Y., & Zhang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.045 · Cited by 5
Miao, L., Lou, J., Xu, S., Zhang, J., Zhong, Y., Wang, G., Li, Y., Lei, S., Shao, S., Wang, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00231 · Cited by 9
Liu, Y., Kimita, W., Bharmal, S. H., & Petrov, M. S. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103052 · Cited by 6
Tantoush, M., Almaghrabi, Y., Abusbaeh, A., Ahmed, N., Tantush, A., Hamida, B. B., Sagher, M., Sager, M., Abouslima, A., Elbahnasawy, S. E., et al. (2026) · Cureus · doi:10.7759/cureus.102018 · Cited by 7
“Orforglipron functions as a biased GLP-1 receptor agonist, preferentially stimulating cyclic adenosine monophosphate (cAMP) accumulation while minimizing β -arrestin recruitment [17].”
InfluentialAlper, A., Peleg, G., Fagin, A., Shah, P. P., Chowdhury, I. Z., Gonzales, A., & FAILLACE, R. T. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00270-4 · Cited by 7
“…hepatic and vascular effects relatively independent of central appetite suppression, This mechanism supported by preclinical data indicate enhanced hepatic GLP-1 receptor activation, potentially driving direct triglyceride-lowering via reduced VLDL secretion, independent of caloric intake [19, 20].”
Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration
Yang, X., Lin, R., Feng, C., Kang, Q., Yu, P., Deng, Y., & Jin, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111353 · Cited by 6
Amatya, R., Min, K. A., & Shin, M. C. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00566-y · Cited by 5
“LY3502970 in high dose exhibited insulin secretion comparable to that of exendin-4 (Kawai et al. 2020).”
ResultBiophysical screening and characterisation in medicinal chemistry
Bingham, M. J., Pesnot, T., & Scott, A. D. (2023) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2023.10.002 · Cited by 6
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Zhou, J., Wang, F., & Li, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1646956 · Cited by 3
“Due to orforglipron ’ s stronger impact on cyclic adenosine monophosphate (cAMP) signalling compared with beta ( b )-cell recruitment, its lower risk of receptor desensitisation distinguishes it from other GLP-1 RAs (10).”
Orforglipron in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2594493 · Cited by 4
“Recent advances have enabled the development of novel oral non-peptide GLP-1RAs, of which orforglipron (LY3502970) is the most notable example [5].”
InfluentialJamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02635-8 · Cited by 3
Hammad, N., Ramadan, A. M., Nazmy, A., Elazab, A., & Abdelaziz, A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261420404 · Cited by 4
Patient preferences for pharmacological treatments for obesity: The VOICE study
Houle, C. R., Gelhorn, H. L., Cutts, K. N., Samuelson, A., & Xavier, N. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100278 · Cited by 4
“Orforglipron does not have specific administration requirements related to food or beverage intake, and no cold-chain requirements [29 – 31].”
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
“Orforglipron is a once-daily, oral small-molecule, (non-peptide) GLP-1 receptor agonist [10, 11], approved for weight management and under investigation for T2D [12–19].”
Wu, Y., Chmiel, A. F., & Bronson, J. J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03492 · Cited by 4
Shirley, M. (2026) · Drugs · doi:10.1007/s40265-026-02363-5 · Cited by 3
“Oral administration of orforglipron resulted in glucose lowering in transgenic mice expressing the human GLP-1 receptor [12].”
InfluentialTanada, M., & Shiraishi, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00021-8 · Cited by 4
Je, I., Kim, T.-K., Lee, H. J., Lee, M. Y., An, K., Park, J.-T., & Kim, K.-Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178143 · Cited by 3
"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024)
Tolkacheva, E. V., Saliev, A. Y., Salakhov, T. L., Balakin, K. V., Ivanov, R. A., & Chernyshov, V. V. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673366258250710101146 · Cited by 3
Elucidating the Structure and Activation Mechanisms of GPCRs Using Modern Computational and AI Tools
Uba, A. İ. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01977-y · Cited by 3
“These bound to various G protein subtypes have provided insight into the structural underpinnings of biased agonism and signaling specificity [ 16 , 17 ].”
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Morse, B. L., Coutant, D. E., Ma, X., Raha, S., Aithal, K., Nicoll, C., Rougée, L. R. A., & Bhattachar, S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70377 · Cited by 4
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
“Notably, the selected cell lines are of human origin, as orforglipron is known to selectively activate the human GLP-1R but to not bind or activate the wild-type mouse/rat GLP-1R [57,58].”
Glucagon receptor family in GtoPdb v.2023.1
BATAILLE, D., Chan, S. L. F., Delagrange, P., Drucker, D. J., Göke, B., Hills, R., Mayo, K. E., Miller, L. J., Salvatori, R., & Thorens, B. (2023) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f29/2023.1 · Cited by 2
ADVANCES TOWARD AN ORAL NON-PEPTIDE AGONIST OF THE GLP-1 RECEPTOR
Fields, T. R., Woerly, E. M., Bell, M. G., Sloop, K. W., & Ho, J. D. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch05 · Cited by 2
Self-citationStructure-activity relationships of thiadiazole agonists of the human secretin receptor
Ardecky, R., Dengler, D. G., Harikumar, K. G., Abelman, M. M., Zou, J., Kramer, B. A., Reddy, S., Olson, S., Ly, A., Puvvula, N., et al. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.100176 · Cited by 2
“While it has been challenging to develop small molecule agonists for this class of receptors due to the characteristic open helical bundle and the absence of classical deep pocket sites of docking [1], there are finally examples of similar success emerging for other members of this family [2].”
BackgroundInfluentialExploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R
Xu, M., Vogel, H., & Yuan, S. (2025) · Molecules · doi:10.3390/molecules30153216 · Cited by 3
“Consequently, the development of oral small-molecule agonists has emerged as an alternative approach, offering advantages such as improved patient compliance and bioavailability through oral administration [27–29].”
GLP1-receptor-agonisták a 2-es típusú diabetes vércukorcsökkentő kezelésében
Winkler, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32547 · Cited by 3
Retatrutide - revolutionary recently developed GLP agonist - literature review
Brzozowska, P., Frańczuk, A., Nowińska, B., Makłowicz, A., Palacz, K. A., & Lenartowicz, I. (2024) · Quality in Sport · doi:10.12775/qs.2024.15.52125 · Cited by 1
Animal models for development of anti-obesity drugs in the age of GLP-1 agents
Culver, A. E., Stayrook, K. R., Comerota, M. M., Oblak, A. L., & Burris, T. P. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2507766 · Cited by 2
“However, the structural and functional differences between human and murine GLP-1 receptors present significant challenges in preclinical development [12].”
Pu, J., Huang, Y., Wan, L., Zhu, M., Wei, H., Gao, H., Zhong, L., Tang, C., & Xu, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16610 · Cited by 2
One small molecule for man, one giant leap for mankind with obesity
Novikoff, A., & Müller, T. D. (2025) · Med · doi:10.1016/j.medj.2025.100924 · Cited by 1
Chen, Y., Li, J., Delemotte, L., & Mu, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00224 · Cited by 1
Li, M., Fang, J., Qi, G., Guo, S., Xu, T., Lu, Y., Yuan, Q., Wang, J., Zhu, S., Shen, J., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00077 · Cited by 3
Galiano, Á., & Notario-Pérez, F. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00836-z · Cited by 1
“[ 137 ], the binding of orforglip-ron to its receptor involves a specific pocked defined by 20 key residues.”
Emara, A., Emara, M., Mansour, A., Elkholy, M., Abbas, O., Abdul‐Hafez, H. A., Azzawi, M. A. D. A., & Shubietah, A. R. M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02218-9 · Cited by 1
“Current clinical guidelines already emphasize the central role of GLP-1 receptor agonists in the management of both obesity and T2DM, particularly in patients with high cardiometabolic risk [17, 30].”
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
Pharmacotherapy of Type 2 Diabetes Mellitus
Jha, P. K., Shukla, H., Makwana, A., & Kakkad, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002309 · Cited by 4
Li, Z., Chen, X., Vong, J. S. L., Zhao, L., Huang, J., Yan, L. Y. C., Ip, B. Y. M., Wing, Y. K., Lai, H. M., Mok, V., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.21.423879
Pancreatic Brsk2 amplifies parasympathetic signals to promote type 2 diabetesPreprint
Xu, R., Wang, K., Yao, Z., Li, J., Pang, J., Zhou, Y., Wang, K., Liu, D., Zhang, Y., Sun, P. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.05.455219
An inverse agonist of orphan receptor GPR61 reveals a novel allosteric mechanismPreprint
Lees, J. A., Dias, J. M., Rajamohan, F., Fortin, J., O’Connor, R., Kong, J., Hughes, E. A. G., Fisher, E. L., Tuttle, J. B., Lovett, G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.01.538732
Zhao, L., He, Q., Yuan, Q., Gu, Y., He, X., Li, J., Wang, K., Li, Y., Shen, J., & Xu, H. E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.08.544171
NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023
Lin, D. W., Armstrong, M., Jiang, J. B., del Pozo, J., & Teijaro, C. N. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch18
Deganutti, G., Pipitò, L., Rujan, R., Weizmann, T., Griffin, P., Ciancetta, A., Moro, S., & Reynolds, C. A. (2024) · eLife · doi:10.7554/elife.96513.2
Multi‐target Peptides for the Treatment of Metabolic Diseases
Bossart, M., & Heßler, G. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch20
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
Modder, M., Tomás, A., Afkir, S., Pronk, A. C. M., Streefland, T. C. M., Lalai, R. A., van Eenige, R., Rensen, P. C. N., Jones, B. J., & Kooijman, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16374
Deganutti, G., Pipitò, L., Rujan, R., Weizmann, T., Griffin, P., Ciancetta, A., Moro, S., & Reynolds, C. A. (2025) · eLife · doi:10.7554/elife.96513.3 · Cited by 2
Zhao, W., Yin, Y., Shi, Z., Yang, K., Li, X., Yang, Y., Jing, T., & Kang, Z. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11213-7 · Cited by 1
Khaled, S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5465445
Mimicking Complex Receptor Actions with Small(ish) Molecules
Lowe, D. (2025) · New England Journal of Medicine · doi:10.1056/nejme2511368
Fang, H., Sun, X., Ding, Y., Gu, S., Niu, B., & Chen, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311548
“Such binding enhances cAMP generation significantly [17–19].”
Rakib, M. A., & Kim, Y. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157666 · Cited by 1
Cline, L., & Wilson, E. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.002 · Cited by 1
A potent novel small molecule GLP-1R agonist identified by rational design and CADD
Chen, J., Yao, Y., & Li, H. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118578 · Cited by 1
Andréelli, F. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.005
Oral GLP-1 receptor agonists: competition for efficacy and tolerability
Nauck, M. A., & Horowitz, M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00360-0
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“Non-peptide GLP1-RAs, such as orforglipron and danuglipron, are a class of weight-lowering drugs specifically designed to overcome some limitations deriving from the biological structure of currently commercialized GLP1-RAs [78,79].”
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“Consequently, reduced β -arrestin engagement has been associated with enhanced GLP-1 RA efficacy [60, 61].”
Discovery of a new GLP-1 receptor agonist using DNA encoded-libraries and similarity search
Lee, J. H., Kim, D., Jeon, H., Park, S. B., Koh, B., Lim, B., Lee, K. A., Choi, K. J., Kim, S. S., Kwon, Y., et al. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103415 · Cited by 1
Fadini, G. P., Morieri, M. L., Boscaro, C., Bonora, B. M., & Cignarella, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70840 · Cited by 1
“Whether this will hold true for future oral GLP-1RA, such as orforglipron [20, 21], remains to be determined, as small molecule agents usually show less variable absorption profiles.”
A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist
Singh, A., Shadangi, S., & Rana, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789257
“Notably, non-peptide small-molecule agonists of the GLP-1R are also being developed for oral bioavailability (Knudsen et al., 2007; Kawai et al., 2020; Griffith et al., 2022).”
Zhang, C.-Y., & Yang, M. (2026) · World Journal of Hepatology · doi:10.4254/wjh.120178
Castro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
Regulators of appetite in mammals—old and new players
Fernandes, J. H., Silva, J. D., Costa, M. D., & Maciel, P. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag020 · Cited by 1
Huang, C., Ying, Y., Wu, Y., Cai, S., Ye, L., Huang, X., Wang, L., & Wang, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70931
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
FragScan: A Quantitative Fragment Scanning Strategy for Rational Drug Discovery
Liu, X. M., Wu, X., Chang, R., Zhao, F., Sun, Z., & Zhang, J. Z. H. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c01187
Lead-guided prodrug development of small molecules as GLP-1R agonists
Lentschat, H., Aboelfotouh, H. G., Nabil, P., Abdallah, M., Khalifa, H., Stichel, J., Abdel‐Halim, M., Abadi, A. H., & Beck‐Sickinger, A. G. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110210 · Cited by 1
BoltzMol-1: Towards Reliable Virtual Screening for Fast and Cost-Effective Hit DiscoveryPreprint
Getz, N., Smith, G., Colgan, A. C., Fan, V., Cavalleri, L., Capponi, F., Wohlwend, J., Gitter, A., Kritzer, J. A., Maiorano, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.04.736485 · Cited by 1
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
“Orforglipron (originally OWL833 or LY3502970) was developed as a small molecule activator for the GLP-1 receptor from molecular screening followed by traditional structural activity relationship studies [25].”
Metadata
- Authors
- Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., Kobilka, T. S., Coghlan, M. P., Willard, F. S., Kawabe, Y., Kobilka, B. K., & Sloop, K. W.
- Affiliations
- Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
- ConfometRx (United States) (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Suzuki, Yoshiyuki
- Kobilka, Brian K.
- Sloop, Kyle W.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-11-11
- Volume
- 117
- Issue
- 47
- Pages
- 29959-29967
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7703558
- OpenAlex
- W3099724881
- Cited by
- 231
- References
- 51
- Citations by year
- 2026: 68 · 2025: 53 · 2024: 44 · 2023: 30 · 2022: 19 · 2021: 15 · 2020: 2
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, class B G protein-coupled receptors, receptor structure, partial agonism, biased signaling, G protein activation, beta-arrestin, oral antidiabetic drugs, type 2 diabetes, insulin secretion, blood glucose reduction, non-human primates
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Protein Domains, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Aminopyridines, Animals, Benzamides, Humans, Hypoglycemic Agents, Macaca fascicularis, Male, Mice, Transgenic, Models, Molecular, Species Specificity, Swine, Tryptophan, Mutagenesis, Site-Directed, Anti-Obesity Agents, Cryoelectron Microscopy, Mice, Rats, Incretins, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.